Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it comes to the prognostic properties the situation is different. Despite the fact that it is more than 20 years ago since the first studies demonstrating an association between a positive HER2 status and poor prognosis were published the issue is still controversial. In this current systematic review a large number of studies on HER2 and gastric cancer have been reviewed. The studies included in this review should fulfill the following two criteria. First criterion: The number of patients in each study should be ≥ 100, and the HER2 status should have been determined e...
Introduction: HER2 overexpression is present in 7 to 34% of gastric carcinomas. Several studies have...
Introduction Patients with the same stage of malignancy often have different life-span, which mak...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...
Background: HER2 is an important biomarker in gastric and gastroesophageal junction tumors. Expressi...
With the availability of a therapeutic target and an effective agent in trastuzumab, a systematic ex...
Objectives. HER2 expression in gastric cancer (GC) has received attention as a ...
Copyright © 2012 Agnieszka Halon et al. This is an open access article distributed under the Creativ...
According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with ...
[Background] A recent randomized controlled trial (Trastuzumab for Gastric Cancer [ToGA] study) esta...
In this study, we investigated the rate of human epidermal growth factor receptor 2 (HER2) overexpre...
HER2 expression in gastric cancer (GC) has received attention as a potential target for therapy with...
BACKGROUND: HER2 protein expression in gastric carcinoma, in correlation with existing, acknowledged...
In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median ov...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in ga...
Introduction: HER2 overexpression is present in 7 to 34% of gastric carcinomas. Several studies have...
Introduction Patients with the same stage of malignancy often have different life-span, which mak...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...
Background: HER2 is an important biomarker in gastric and gastroesophageal junction tumors. Expressi...
With the availability of a therapeutic target and an effective agent in trastuzumab, a systematic ex...
Objectives. HER2 expression in gastric cancer (GC) has received attention as a ...
Copyright © 2012 Agnieszka Halon et al. This is an open access article distributed under the Creativ...
According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with ...
[Background] A recent randomized controlled trial (Trastuzumab for Gastric Cancer [ToGA] study) esta...
In this study, we investigated the rate of human epidermal growth factor receptor 2 (HER2) overexpre...
HER2 expression in gastric cancer (GC) has received attention as a potential target for therapy with...
BACKGROUND: HER2 protein expression in gastric carcinoma, in correlation with existing, acknowledged...
In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median ov...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in ga...
Introduction: HER2 overexpression is present in 7 to 34% of gastric carcinomas. Several studies have...
Introduction Patients with the same stage of malignancy often have different life-span, which mak...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...